---
title: "Economic value of gonorrhea resistance testing in the US: cost-neutral price thresholds"
id: "plos-medicine-0-economic-value-of-gonorrhea-resistance-testing-in-the-united-states-a-multi"
canonical_url: "https://medichelpline.com/clinical-feed/plos-medicine-0-economic-value-of-gonorrhea-resistance-testing-in-the-united-states-a-multi"
content_type: "clinical_feed_article"
specialty: "Infectious Disease"
source_name: "PLOS Medicine"
source_url: "https://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1005073"
published_at: "2026-11-17T14:00:00.000Z"
evidence_level: "Journal Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Economic value of gonorrhea resistance testing in the US: cost-neutral price thresholds
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/plos-medicine-0-economic-value-of-gonorrhea-resistance-testing-in-the-united-states-a-multi
- **Specialty:** [Infectious Disease](https://medichelpline.com/clinical-feed/infectious-disease.md)
- **Primary Source:** PLOS Medicine
- **Source URL:** [Original Journal Publication](https://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1005073)
- **Published At:** 2026-11-17T14:00:00.000Z
- **Evidence Rating:** Journal Feed
## Executive GIST (TL;DR)
- The study modeled the economic value of resistance testing for **gonorrhea** across three test strategies: ciprofloxacin-only, ciprofloxacin + **ceftriaxone**, and a triple-target panel including a hypothetical novel agent. The simulation was individual-level and stochastic. - Investigators incorporated US infection prevalence, symptom status, diagnostic accuracy, resistance profiles, treatment pathways, partner management, and 2025 US dollar costs. - Outcomes measured: per-episode direct medical cost savings, system-level costs from rising **ceftriaxone** resistance among men who have sex with men (MSM), and avoided antibiotic-development costs. - Per-episode break-even (cost-neutral) prices ranged from near $0 when **ceftriaxone** resistance was absent to up to $48 per test at 15% **ceftriaxone** resistance. - At 50% ciprofloxacin resistance and 5% **ceftriaxone** resistance, thresholds were $7 (single-target) and $13 (triple-target), with reported 95% uncertainty intervals. - For MSM, adding system-level resistance emergence and avoided development costs raised per-test values substantially (single-target $31–$114; triple-target $73–$106), depending on prescribing shifts at 5% **ceftriaxone** resistance. - The model assumed resistance results were available during the same clinical visit and did not model transmission dynamics, co-resistance, or patient quality-of-life impacts. - Authors provided code and data in a public GitHub and Zenodo archive for reproducibility, and noted limitations in applicability beyond MSM for longer-term value estimates.
## Clinical Analysis & Structured Key Points
[ Skip to main content ](https://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1005073#main-content) Advertisement * [plos.org](https://plos.org/) * [Create account](https://community.plos.org/registration/new) * [Sign in](https://journals.plos.org/user/secure/login?page=%2Fplosmedicine%2Farticle%3Fid%3D10.1371%2Fjournal.pmed.1005073) * * About * Browse * Publish * [](https://journals.plos.org/plosmedicine/ "PLOS Medicine") * Search [advanced search](https://journals.plos.org/plosmedicine/search) * 0 [Save](https://journals.plos.org/plosmedicine/article/metrics?id=10.1371/journal.pmed.1005073#savedHeader) [Total Mendeley and Citeulike bookmarks.](https://journals.plos.org/plosmedicine/article/metrics?id=10.1371/journal.pmed.1005073#savedHeader) * 0 [Citation](https://journals.plos.org/plosmedicine/article/metrics?id=10.1371/journal.pmed.1005073#citedHeader) [Paper's citation count computed by Dimensions.](https://journals.plos.org/plosmedicine/article/metrics?id=10.1371/journal.pmed.1005073#citedHeader) * 38 [View](https://journals.plos.org/plosmedicine/article/metrics?id=10.1371/journal.pmed.1005073#viewedHeader) [PLOS views and downloads.](https://journals.plos.org/plosmedicine/article/metrics?id=10.1371/journal.pmed.1005073#viewedHeader) * 0 [Share](https://journals.plos.org/plosmedicine/article/metrics?id=10.1371/journal.pmed.1005073#discussedHeader) [Sum of Facebook, Twitter, Reddit and Wikipedia activity.](https://journals.plos.org/plosmedicine/article/metrics?id=10.1371/journal.pmed.1005073#discussedHeader) Open Access Peer-reviewed Research Article # Economic value of gonorrhea resistance testing in the United States: A multi-perspective modeling study * Brooke E. Nichols , Roles Conceptualization, Data curation, Formal analysis, Methodology, Validation, Visualization, Writing – original draft * E-mail: brooken@bu.edu Affiliations Department of Global Health, Boston University School of Public Health, Boston, Massachusetts, United States of America, Amsterdam UMC, location University of Amsterdam, Department of Global Health, Amsterdam Institute for Global Health and Development, Amsterdam, The Netherlands [ ![ORCID logo](https://journals.plos.org/resource/img/orcid_16x16.png) https://orcid.org/0000-0003-4682-4999 ](https://orcid.org/0000-0003-4682-4999 "ORCID Registry") ⨯ * Betsy Wonderly Trainor, Roles Conceptualization, Funding acquisition, Project administration, Supervision, Writing – review & editing Affiliation CARB-X, Boston University, Boston, Massachusetts, United States of America [ ![ORCID logo](https://journals.plos.org/resource/img/orcid_16x16.png) https://orcid.org/0009-0006-7768-4940 ](https://orcid.org/0009-0006-7768-4940 "ORCID Registry") ⨯ * Grace Hampson, Roles Conceptualization, Writing – review & editing Affiliation Office of Health Economics, London, England, United Kingdom ⨯ * Yonatan H. Grad, Roles Conceptualization, Methodology, Writing – review & editing Affiliation Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, United States of America [ ![ORCID logo](https://journals.plos.org/resource/img/orcid_16x16.png) https://orcid.org/0000-0001-5646-1314 ](https://orcid.org/0000-0001-5646-1314 "ORCID Registry") ⨯ * Jeffrey D. Klausner Roles Conceptualization, Supervision, Writing – review & editing Affiliation Department of Population and Public Health Sciences, Keck School of Medicine, University of Southern California, Los Angeles, California, United States of America ⨯ # Economic value of gonorrhea resistance testing in the United States: A multi-perspective modeling study * Brooke E. Nichols, * Betsy Wonderly Trainor, * Grace Hampson, * Yonatan H. Grad, * Jeffrey D. Klausner ![PLOS](https://journals.plos.org/resource/img/logo-plos-full-color.svg) x * Published: November 17, 2026 * * [Article](https://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1005073) * [Authors](https://journals.plos.org/plosmedicine/article/authors?id=10.1371/journal.pmed.1005073) * [Metrics](https://journals.plos.org/plosmedicine/article/metrics?id=10.1371/journal.pmed.1005073) * [Comments](https://journals.plos.org/plosmedicine/article/comments?id=10.1371/journal.pmed.1005073) * [Media Coverage](http://plos.altmetric.com/details/doi/10.1371/journal.pmed.1005073) * [Peer Review](https://journals.plos.org/plosmedicine/article/peerReview?id=10.1371/journal.pmed.1005073) * [Abstract](https://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1005073#abstract0) * [Author summary](https://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1005073#abstract1) * [Introduction](https://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1005073#sec007) * [Methods](https://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1005073#sec008) * [Results](https://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1005073#sec018) * [Discussion](https://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1005073#sec025) * [Supporting information](https://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1005073#sec026) * [Acknowledgments](https://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1005073#ack) * [References](https://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1005073#references) * [Reader Comments](https://journals.plos.org/plosmedicine/article/comments?id=10.1371/journal.pmed.1005073) * [Figures](https://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1005073) [?](https://journals.plos.org/plosmedicine/s/accepted-manuscripts#loc-early-version) ## This is an uncorrected proof. ## Abstract ### Background Rising antimicrobial resistance in _Neisseria gonorrhoeae_ threatens the effectiveness of existing therapies. Ceftriaxone is the only recommended first-line (empiric) treatment for uncomplicated gonorrhea in the United States. Ciprofloxacin is no longer recommended for empiric use because of widespread resistance, but it is inexpensive, taken orally, and effective against susceptible infections, which a resistance test can identify. In the context of rising resistance, resistance-guided treatment (RGT) may reduce treatment failures, complications, and inappropriate use of last-line agents while slowing resistance emergence and preserving the efficacy of new and existing drugs. Understanding where RGT provides economic value—across near-term cost savings, delayed resistance emergence, and avoided antibiotic development costs—can illuminate the broader case for investing in resistance testing and help guide pricing and reimbursement decisions. ### Methods and findings We developed an individual-level stochastic simulation model of gonorrhea diagnosis and treatment in the United States, incorporating infection prevalence, symptom status, diagnostic accuracy, resistance profiles, treatment pathways, and partner management (costs in 2025 US dollars[USD]). We evaluated three resistance testing strategies, ciprofloxacin-only, ciprofloxacin + ceftriaxone, and triple-target (including a novel drug A), across a wide range of resistance scenarios. We quantified economic value across three dimensions: (1) per-episode direct medical cost savings, (2) system-level costs attributable to ceftriaxone resistance emergence among men who have sex with men (MSM), and (3) avoided costs of new antibiotic development, estimating the maximum per-test price at which RGT remains cost-neutral. Per-episode cost-neutrality thresholds ranged from near $0 when ceftriaxone resistance was absent to up to $48 per test at 15% prevalence of ceftriaxone resistance (proportion of infections resistant to ceftriaxone). At a prevalence of 50% ciprofloxacin resistance and 5% ceftriaxone resistance, the population-weighted threshold was $7 (95% uncertainty interval [UI] ($3, $11) for a ciprofloxacin-only test and $13 (95% UI [$8–$19]) for a triple-target test. Among MSM, incorporating system-level resistance emergence costs and avoided antibiotic development costs increased the total per-test value to $31 to $114 for a single-target test and $73 to $106 for a triple-target test, depending on whether prescribing practices shift when ceftriaxone resistance reaches 5%. The main limitations are that the model assumes resistance results are available at the same clinical visit to guide initial treatment, does not represent onward transmission or co-resistance between antibiotics, and could estimate longer-term value only for MSM. ### Conclusions Resistance-guided therapy offers economic benefits across multiple dimensions even at relatively high diagnostic prices, supporting investment in gonorrhea resistance testing to improve partner outcomes, delay resistance emergence, and enhance the long-term cost-efficiency of gonorrhea management. ## Author summary ### Why was this study done? * Rising antimicrobial resistance in _Neisseria gonorrhoeae_ threatens the effectiveness of ceftriaxone, the only remaining recommended empiric therapy. Preserving new and existing drugs is a public health priority. * Resistance-guided therapy could reduce treatment failures and complications, improve partner treatment, and slow resistance at the population level, but it is unclear how much such a test could cost and still be worthwhile, or over which time horizons its value accrues. ### What did the researchers do and find? * We built a simulation model of gonorrhea testing and treatment in the United States and estimated the highest price at which a resistance test would still break even against standard care, separately for three kinds of value: savings within the current episode of care, future health-system costs avoided by slowing the rise of ceftriaxone resistance, and avoided costs of developing a new antibiotic. * Break-even prices within a single episode of care were near zero while ceftriaxone resistance was rare, as it now is in the United States, but rose to $48 per test once 15% of infections were resistant to ceftriaxone. Among men who have sex with men, this break-even price was roughly $31 to $114 per test for a single-target test and $73 to $106 for a triple-target test once the two longer-term kinds of value were included. * How a test is used mattered as much as what it detects: the triple-target panel had a lower per-test value in some scenarios because its long-term benefit required testing far more people. ### What do these findings mean? * A resistance test for gonorrhea could carry a fairly high price and still save the health system money, particularly once the value of keeping existing antibiotics working is counted alongside the immediate savings from better-targeted treatment. * Value accrues across several distinct dimensions at once (better outcomes for patients and their partners, delayed emergence of resistance, and deferred spending on new antibiotic development), and separating them gives payers, guideline bodies, and diagnostic developers a framework for pricing, reimbursement, and adoption decisions. * The main limitations are that we assumed resistance results would be available during the same clinical visit (value fell by over 80% when treatment was given before results returned), did not model how gonorrhea spreads between people, counted only direct medical costs rather than benefits to patients’ health or quality of life, and could estimate longer-term value only for men who have sex with men. ## Figures ![Fig 3](https://journals.plos.org/plosmedicine/article/figure/image?size=inline&id=10.1371/journal.pmed.1005073.g003) ![Fig 4](https://journals.plos.org/plosmedicine/article/figure/image?size=inline&id=10.1371/journal.pmed.1005073.g004) ![Table 2](https://journals.plos.org/plosmedicine/article/figure/image?size=inline&id=10.1371/journal.pmed.1005073.t002) ![Table 1](https://journals.plos.org/plosmedicine/article/figure/image?size=inline&id=10.1371/journal.pmed.1005073.t001) ![Fig 1](https://journals.plos.org/plosmedicine/article/figure/image?size=inline&id=10.1371/journal.pmed.1005073.g001) ![Fig 2](https://journals.plos.org/plosmedicine/article/figure/image?size=inline&id=10.1371/journal.pmed.1005073.g002) ![Fig 3](https://journals.plos.org/plosmedicine/article/figure/image?size=inline&id=10.1371/journal.pmed.1005073.g003) ![Fig 4](https://journals.plos.org/plosmedicine/article/figure/image?size=inline&id=10.1371/journal.pmed.1005073.g004) ![Table 2](https://journals.plos.org/plosmedicine/article/figure/image?size=inline&id=10.1371/journal.pmed.1005073.t002) ![Table 1](https://journals.plos.org/plosmedicine/article/figure/image?size=inline&id=10.1371/journal.pmed.1005073.t001) ![Fig 1](https://journals.plos.org/plosmedicine/article/figure/image?size=inline&id=10.1371/journal.pmed.1005073.g001) ![Fig 2](https://journals.plos.org/plosmedicine/article/figure/image?size=inline&id=10.1371/journal.pmed.1005073.g002) **Citation:** Nichols BE, Wonderly Trainor B, Hampson G, Grad YH, Klausner JD (2026) Economic value of gonorrhea resistance testing in the United States: A multi-perspective modeling study. PLoS Med 23(11): e1005073. https://doi.org/10.1371/journal.pmed.1005073 **Academic Editor:** Mirjam E. E. Kretzschmar, University Medical Centre Utrecht: Universitair Medisch Centrum Utrecht, NETHERLANDS, KINGDOM OF THE **Received:** April 7, 2026; **Accepted:** November 9, 2026; **Published:** November 17, 2026 **Copyright:** © 2026 Nichols et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. **Data Availability:** All data underlying the findings are contained within the manuscript and [Supporting information](https://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1005073#sec026), and the values plotted in Figs 2–4 are provided in S1 Data. The R code used to run the simulation model, generate the per-episode and threshold estimates (Figs 2–4 and Table 2), and produce the deterministic sensitivity analysis ([S1 Appendix](https://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1005073#pmed.1005073.s001)) is available from GitHub ([https://github.com/nicholslab/gonorrhea_res_testing)](https://github.com/nicholslab/gonorrhea_res_testing) and archived in Zenodo (DOI: (for the current version), and DOI: (for the original submitted version)). The repository includes a README with instructions for reproducing the reported results and the random seeds required for reproducibility. The repository also includes all results files used to generate the final figures. **Funding:** This work was supported by CARB-X ( ) (to BEN and BWT; no award number). CARB-X’s funding for this work comes from: the US Department of Health and Human Services (HHS) ( ), Administration for Strategic Preparedness and Response, Biomedical Advanced Research and Development Authority (BARDA) under agreement number 75A50122C00028 ( ), and by awards from Wellcome (WT224842) ( ), the UK Department of Health and Social Care’s Global Antimicrobial Resistance Innovation Fund (GAMRIF) ( ), the Gates Foundation (OPP1192072) ( ), Germany’s Federal Ministry of Research, Technology and Space (BMFTR) ( ), the Novo Nordisk Foundation ( ), Italy’s Ministry of Economy and Finance (MEF) ( ), Japan’s Ministry of Health ( ), the European Commission’s DG Health Emergency Preparedness and Response Authority (DG HERA) ( ), and KfW Development Bank ( ). The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), provides support in the form of in-kind services through access to a suite of preclinical services for product development ( ). CARB-X supported the time of BEN through funds paid to BEN’s institution, and supported BWT in the form of salary as a CARB-X employee. BWT contributed to study conceptualization, project administration, and preparation of the manuscript. Other than through the contributions of BWT as an author, the funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. **Competing interests:** I have read the journal’s policy and the authors of this manuscript have the following competing interests: BEN’s institution received support for the work reported in this manuscript from CARB-X. BWT is a paid employee of CARB-X, which provided support for this work. GH is an employee of the Office of Health Economics, which receives funding from a range of public and private sources, including the pharmaceutical industry. YHG reports grants paid to his institution from the National Institutes of Health, the Bill & Melinda Gates Foundation, and GARDP; consulting fees from CARB-X and from Analysis Group/GSK; travel support from the Gates Foundation to attend the Grand Challenges Meeting; and service on the scientific advisory boards of Kanso Diagnostics, Decoy Therapeutics, and Claryx. JDK has declared that no competing interests exist. This does not alter our adherence to the journal’s policies on sharing data and materials. BEN is on Editorial Board. **Abbreviations:** AST, antimicrobial susceptibility test; CHEERS, Consolidated Health Economic Evaluation Reporting Standards; CPP, chronic pelvic pain; CPT, Current Procedural Terminology; DGI, disseminated gonococcal infection; EP, ectopic pregnancy; GISP, Gonococcal Isolate Surveillance Project; NDA, novel drug A; PID, pelvic inflammatory disease; RGT, Resistance-guided treatment; RPR, Rapid plasma reagin; TI, tubal infertility; UI, uncertainty interval ## Introduction Gonorrhea remains a pressing global public health concern, with an estimated 82 million incident cases annually [[1](https://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1005073#pmed.1005073.ref001)]. Rising antimicrobial resistance in _Neisseria gonorrhoeae_ threatens the effectiveness of ceftriaxone, which is the only remaining recommended empiric therapy [[2](https://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1005073#pmed.1005073.ref002),[3](https://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1005073#pmed.1005073.ref003)]. The spread of resistant strains has prompted urgent calls for both novel therapeutics and improved diagnostic strategies to guide tailored treatment. Two new antimicrobials, zoliflodacin and gepotidacin, are starting to enter the market [[4](https://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1005073#pmed.1005073.ref004)–[6](https://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1005073#pmed.1005073.ref006)], but preserving their long-term efficacy will be critical to avoid repeating the cycle of rapid resistance emergence that has characterized much of gonorrhea treatment over the past century [[7](https://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1005073#pmed.1005073.ref0
## Related Clinical Research

- [Bacterial profile and mortality predictors in necrotizing fasciitis — multicentre Uganda study](https://medichelpline.com/clinical-feed/pubmed-43049839.md) (DOI: 10.1007/s15010-026-02767-1)
- [Economic value of gonorrhea resistance testing in the US: multi-perspective model](https://medichelpline.com/clinical-feed/pubmed-43043955.md) (DOI: 10.1371/journal.pmed.1005073)
- [Clinical and epidemiological profile of invasive non-typhoidal Salmonella disease in Ghana](https://medichelpline.com/clinical-feed/plos-one-23-clinical-and-epidemiological-characteristics-of-invasive-non-typhoidal.md)
- [Multidrug-resistant Salmonella in Fruit Bats and Shared Water Sources in Bangladesh](https://medichelpline.com/clinical-feed/plos-one-22-ecology-and-epidemiology-of-multidrug-resistance-salmonella-in-fruit-bats-and.md)
- [Metamycoplasma gateae Osteomyelitis After Cat Bite: Case Report and Clinical Details](https://medichelpline.com/clinical-feed/cdc-emerging-infectious-diseases-journal-3-osteomyelitis-caused-by-metamycoplasma-gateae-after-cat-bite-japan-2026.md)

## Navigation
- [← Back to Infectious Disease Feed](https://medichelpline.com/clinical-feed/infectious-disease.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.